SUNNYVALE, Calif., Aug. 9, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
Wedbush PacGrow Life Sciences Conference, New York, NY
Wednesday, August 15, 2012 at 10.20 a.m. Eastern Time
Baird Health Care Conference, New York, NY
Thursday, September 6, 2012 at 12.10 p.m. Eastern Time
Morgan Stanley Global Healthcare Conference, New York, NY
Wednesday, September 12, 2012 at 9.45 a.m. Eastern Time
UBS Global Life Sciences Conference, New York, NY
Thursday, September 20, 2012 at 9.30 a.m. Eastern Time
Credit Suisse Small & Mid Cap Conference, New York, NY
Friday, September 21, 2012 at 8.00 a.m. Eastern Time
Additionally, Cepheid announced that it will host an Analyst Event featuring management presentations and a question and answer session in New York, NY on Thursday, September 27, 2012 starting at 8.00 a.m. Eastern Time. Attendance at the event is by invitation only, although Cepheid welcomes all interested parties to access the proceedings via a live audio webcast as detailed below.
Accessing Live Webcasts
To access the live webcasts for these events, please visit Cepheid's website at http://ir.cepheid.com at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcasts will be available shortly following the presentation and will remain available for at least 90 days.
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.
For Media Inquiries:
For Investor Inquiries:
Cepheid Corporate Communications
Cepheid Investor Relations
Tel: (408) 400-8377
Tel: (408) 400-8329